Vertex Pharmaceuticals INC / Ma 8-K Filing
Ticker: VRTX · Form: 8-K · Filed: Nov 3, 2025 · CIK: 875320
Sentiment: neutral
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-11-03 16:06:19
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 Par Value Per Share VRTX The Nasdaq G
Filing Documents
- vrtx-20251103.htm (8-K) — 24KB
- ex-991_q32025.htm (EX-99.1) — 241KB
- 0000875320-25-000230.txt ( ) — 405KB
- vrtx-20251103.xsd (EX-101.SCH) — 2KB
- vrtx-20251103_lab.xml (EX-101.LAB) — 21KB
- vrtx-20251103_pre.xml (EX-101.PRE) — 12KB
- vrtx-20251103_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 3, 2025, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and nine months ended September 30, 2025. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Description of Document 99.1 Press Release Dated November 3 , 2025. 104 Cover Page Interactive Data File — the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERTEX PHARMACEUTICALS INCORPORATED (Registrant) Date: November 3, 2025 /s/ Jonathan Biller Jonathan Biller Executive Vice President, Chief Legal Officer